OncLive® Expands its Strategic Alliance Partnerships With University of Kentucky's Markey Cancer Center

Article

In Partnership With:

Kentucky's only NCI cancer center, Markey focuses on bringing the latest therapies to its home state.

OncLive® and the Markey Cancer Center at the University of Kentucky (UK) have joined forces with a new Strategic Alliance Partnership, the company announced today. A National Cancer Institute-designated cancer center, the UK Markey Cancer Center strives to be the best source of care and information for the people of Kentucky. OncLive’s editorial and marketing groups will keep its readers abreast of the latest announcements coming from Markey.

The Center's mission is to reduce cancer mortality through a comprehensive program of cancer research, treatment, education and community engagement with a particular focus on the underserved Appalachian population of eastern Kentucky. In fact, Markey is the only NCI-designated cancer center focused on the health of the central Appalachian population, which represents one of the most economically-disadvantaged, disease-burdened and medically underserved regions in the U.S.

Markey's 130+ members hold appointments in 27 departments in eight colleges across the university and are organized into four thematic research programs: Cancer Cell Biology and Signaling; Cancer Prevention and Control; Drug Discovery, Delivery and Translational Therapeutics and Genomic Instability and Metabolism. To support and complement their research, Markey members have access to established shared resource facilities, including Biospecimen and Tissue Procurement, Biostatistics and Bioinformatics, Cancer Research Informatics, Flow Cytometry and Cell Sorting and Free Radical Biology and Metabolism.

“The Markey Cancer Center is involved in crucial work in implementing new cancer therapies, uncovering innovative treatments and learning more about the roots of the disease,” said Mike Hennessy Jr., president of Intellisphere Oncology and Healthcare Specialty Group, part of the Plainsboro, N.J.-based Michael J. Hennessy Associates, Inc. (MJH), family of businesses. “We look forward to sharing more such news in the future.”

Markey's clinical and research work is backed by UK, the Commonwealth of Kentucky, and philanthropy through the Markey Cancer Foundation. In fact, since 2009, more than $185 million in institutional, state and philanthropic funds has supported the recruitment of cancer researchers and clinician scientists and the construction and renovation of clinical and state-of-the-art research space specifically for the oncology research and clinical programs at UK.

“We offer our deep knowledge, experience and expertise in discussions about cancer,” said Dr. B. Mark Evers, director of the Markey Cancer Center. “We look forward to working with OncLive to help broaden our reach as we continue our efforts to understand and treat cancer.”

OncLive’s Strategic Alliance Partnerships include more than 55 leading cancer centers, nursing schools and physician groups around the country. “The Strategic Alliance Partnership program serves everyone committed to fighting cancer,” said Hennessy. “When we work together and share our knowledge broadly, we are better armed to improve our efforts to overcome this devastating disease.”

About OncLive

OncLive.com is the official website for Intellisphere’s Oncology Specialty Group, which publishes Oncology & Biotech News, OncologyLive, Oncology Nursing News and Contemporary Oncology. OncLive offers oncology professionals resources and information they need to provide the best care for their patients. Intellisphere, LLC, a leading provider of healthcare publishing, research and education, is part of the Michael J. Hennessy Associates, Inc., family of businesses, based in Plainsboro, N.J. 

MJH is also the parent company of CURE Media Group, which includes CURE® magazine, the largest consumer publication in the U.S. focused entirely on cancer, and curetoday.com, the magazine’s online resource. CURE reaches patients, cancer centers and advocacy groups, and combines science and humanity to make cancer understandable. For more information, visit www.onclive.com/, www.curetoday.com or www.mjhassoc.com/.

About the Markey Cancer Center

The Markey Cancer Center was founded in 1983 and is a dedicated matrix cancer center established as an integral part of the University of Kentucky (UK) and the UK HealthCare enterprise. Markey functions as a multifaceted, multidisciplinary complex whose mission is to reduce cancer morbidity and mortality through a comprehensive program of cancer education, research, treatment and community engagement.

The clinical programs and services of the Markey Cancer Center are integrated with the UK Albert B. Chandler Hospital. Markey's cancer specialty teams work together with UK Chandler Hospital departments and divisions to provide primary patient care and support services, as well as advanced specialty care with applicable clinical research studies. All diagnostic services, clinical and pathology laboratories, operating rooms, emergent and intensive care and radiation therapy services are also provided to cancer patients through UK Chandler Hospital. Attending physicians affiliated with the Center are board-certified in their respective oncologic specialties, and its research scientists are generously funded by nationally prominent funding agencies, including the National Cancer Institute.

For more information, please visit http://ukhealthcare.uky.edu/Markey/.

Related Videos
Aman Chauhan, MD, of the University of Kentucky
Reema A. Patel, MD, of University of Kentucky
Michael J. Cavnar, MD, discusses the use of hepatic artery infusion pumps in patients with colorectal cancer with liver metastases.
Joseph Kim, MD
Reema A. Patel, MD
Michael J. Cavnar, MD
Prakash Pandalai, MD
Prakash Pandalai, MD, ​discusses the use of cytoreductive surgery plus heated intraperitoneal chemotherapy in the treatment of patients with colorectal peritoneal carcinomatosis.
Joseph Kim, MD, discusses the multidisciplinary management of hepatocellular carcinoma.
Joseph Kim, MD, of University of Kentucky Markey Cancer Center